# EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

> **NCT00129935** · PHASE3 · COMPLETED · sponsor: **Spanish Breast Cancer Research Group** · enrollment: 1384 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Capecitabine
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00129935
- **Lead sponsor:** Spanish Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2013-06
- **Final completion:** 2019-04-04
- **Target enrollment:** 1384 (ACTUAL)
- **Last updated:** 2023-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129935, "EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00129935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*